

Supporting information for:

2-Alkylphosphino-1-Boraadamantanes

Kurt F. Hoffmann^a, Rayni P. Noriega^a, Paul D. Boyle^a and Marcus W. Drover^{*a}

^aDepartment of Chemistry, Western University, 1151 Richmond Street, London, ON, N8K 3G6,
Canada.

marcus.drover@uwo.ca

1. Experimental Section	S2
2. Preparation of Compounds	S3
3. Multinuclear NMR Data	S9
4. Additional Reactions	S29
5. X-Ray Crystallography	S42
6.. Computational Chemistry	S44
7.. References	S49

Experimental Section:

General considerations. All experiments were carried out employing standard Schlenk techniques under an atmosphere of dry nitrogen employing degassed, dried solvents in a solvent purification system supplied by PPT, LLC. Non-halogenated solvents were tested with a standard purple solution of sodium benzophenone ketyl in tetrahydrofuran in order to confirm effective moisture removal. *d*₆-benzene was dried over molecular sieves and degassed by three freeze-pump-thaw cycles. All other reagents were purchased from commercial vendors and used without further purification unless otherwise stated. 3-Methoxy-7-(2-bromoethyl)-3-borabicyclo[3.3.1]non-6-ene (**5**), 2-(3-chloropropyl)-1-boraadamantane (**1**), 2-(2-chloroethyl)-1-boraadamantane (**3**), LiPPh₂, and LiP(*t*-Bu)₂ were prepared according to literature procedures.^[1]

Physical methods. All NMR data were recorded with a Bruker AVIII HD 400 MHz or a Bruker Neo 600 MHz instrument. ¹H NMR spectra are reported in parts per million (ppm) and are referenced to residual solvent e.g., ¹H(C₆D₆): δ = 7.16; ¹³C(C₆D₆): δ = 128.06; coupling constants are reported in Hz. ¹³C, ³¹P, and ¹¹B NMR spectra were performed as proton-decoupled experiments (unless explicitly stated otherwise) and are reported in ppm. Mass spectrometry was carried out with a Bruker micrOTOF 11 using electrospray ionization.


Preparation of Compounds:

General procedure for 2-alkylphosphine-1-boraadamantanes:

In the glovebox, the corresponding 2-chloroalkyl-1-boraadamantane was weighed into a 20 mL scintillation vial equipped with a stir bar and dissolved in 5 mL of THF and precooled to $-35\text{ }^{\circ}\text{C}$. To this solution, the corresponding lithium phosphide dissolved in 10 mL of THF was added dropwise, which resulted in a rapid decolorization. After stirring the mixture for 1 h, all volatiles were removed *in vacuo*, resulting in a cloudy oil. The mixture was extracted with Et₂O, filtered and the filtrate subsequently dried *in vacuo*. The resulting solid was washed with cold *n*-pentane and dried again, yielding a colorless powder.

2-(3-diphenylphosphinopropyl)-1-boraadamantane (2^{Ph}; C₂₄H₃₀BP, 360 g/mol):


2-(3-chloropropyl)-1-boraadamantane (232 mg, 0.82 mmol) was reacted with LiPPh₂ (158 mg, 0.82 mmol, 1 equiv.) according to the general procedure described above. The resulting solid was washed with cold *n*-pentane and dried



again, yielding a colorless powder (200 mg, 67%). Crystals suitable for X-ray diffraction were grown by cooling a concentrated solution in Et₂O to $-35\text{ }^{\circ}\text{C}$ overnight. ¹H NMR (600 MHz, d₁-CDCl₃, 298 K): δ = 7.67 (m, 2H, -PPh₂), 7.45 (m, 8H, -PPh₂), 2.31 (m, 1H), 2.16 (m, 4H), 1.93 (m, 2H), 1.84 (m, 2H), 1.74 (m, 2H), 1.55 (m, 4H), 1.15 (m, 2H), 0.98 (m, 1H), 0.90 (m, 1H), 0.30 (m, 1H). ¹³C{¹H} NMR (101 MHz, d₁-CDCl₃, 298 K): δ = 133.7 (d, *J* = 8.7 Hz), 131.8 (d, *J* = 8.6 Hz), 130.6 (dd, *J* = 24.7, 2.3 Hz), 128.6 (dd, *J* = 9.0, 2.7 Hz), 41.9, 41.1 (d, *J* = 1.5 Hz), 38.2 (d, *J* = 11.7 Hz), 34.3, 32.2 – 31.5 (m), 23.7, 21.0 (d, *J* = 30.4 Hz). ³¹P{¹H} NMR (243 MHz, d₁-CDCl₃, 298 K): δ = -6.6. ¹¹B{¹H} NMR (193 MHz, d₁-CDCl₃, 298 K): δ = -16.3. HRESI(+)-MS: calcd. 360.2173 exptl. 360.2125 for C₂₄H₃₀BP [M]⁺.


2-(2-diphenylphosphinoethyl)-1-boraadamantane (4^{Ph}; C₂₃H₂₈BP, 346 g/mol):

2-(2-chloroethyl)-1-boraadamantane (286 mg, 1.06 mmol) was reacted with LiPPh₂ (192 mg, 1.06 mmol, 1 equiv.) according to the general procedure described above. The resulting solid was washed with cold *n*-pentane and dried again, yielding a




colorless powder (333 mg, 91%). Crystals suitable for X-ray diffraction were grown by cooling a concentrated solution in Et₂O to -35 °C overnight. ¹H NMR (600 MHz, d₁-CDCl₃, 298 K): δ = 7.45 (m, 10H, -PPh₂), 2.68 (m, 1H), 2.30 (m, 1H), 2.20 (m, 1H), 2.10 (m, 1H), 2.05 (m, 1H), 1.97 (m, 1H), 1.85 (m, 2H), 1.70 (m, 1H), 1.60 (m, 1H), 1.53 (m, 1H), 1.16 (m, 2H), 0.83 (m, 1H), 0.67 (m, 1H), 0.56 (m, 1H). ¹³C{¹H} NMR (101 MHz, d₁-CDCl₃, 298 K): δ = 132.5 (dd, J = 24.2, 9.4 Hz, -PPh₂), 130.4 (d, J = 9.8 Hz, -PPh₂), 128.7 (d, J = 9.4 Hz, -PPh₂), 41.1 (d, J = 30.0 Hz), 35.1 (d, J = 11.9 Hz), 33.8, 32.2 (d, J = 13.4 Hz), 27.7 (d, J = 10.2 Hz), 26.6 (d, J = 42.8 Hz). ³¹P{¹H} NMR (243 MHz, d₁-CDCl₃, 298 K): δ = 14.5. ¹¹B{¹H} NMR (193 MHz, d₁-CDCl₃, 298 K): δ = -11.7. HRESI(+)-MS: calcd. 346.2016 exptl. 346.1966 for C₂₃H₂₈BP [M]⁺.

2-(3-di-tert-butylphosphinopropyl)-1-boraadamantane (**2^{t-Bu}**; C₂₀H₃₈BP, 320 g/mol): 2-(3-chloropropyl)-1-boraadamantane (292 mg, 1.03 mmol) was reacted with LiP(*t*-Bu)₂ (157 mg, 1.03 mmol, 1 equiv.) according to the general procedure described above. The product was obtained as colorless crystals



after recrystallization from Et₂O (180 mg, 55%). Crystals suitable for X-ray diffraction were grown by cooling a concentrated solution in Et₂O to -35 °C overnight. ¹H NMR (600 MHz, d₆-C₆D₆, 298 K): δ = 2.56 (m, 2H), 2.27 (m, 1H), 2.21 (m, 1H), 2.11 (m, 3H), 2.03 (m, 1H), 1.94 (m, 1H), 1.85 (m, 1H), 1.78 (m, 1H), 1.60 (m, 1H), 1.50 (m, 1H), 1.40 (m, 1H), 1.33 (m, 3H), 1.27 (m, 2H), 1.10 (d, J = 11.0 Hz, 9H, -P(*t*-Bu)₂), 1.03 (m, 1H), 0.94 (d, J = 11.2 Hz, 9H, -P(*t*-Bu)₂). ¹³C{¹H} NMR (101 MHz, d₆-C₆D₆, 298 K): δ = 42.3, 41.6, 39.1 (d, J = 10.8 Hz), 34.4 (d, J = 4.5 Hz), 34.0 (m), 32.7 (d, J = 12.1 Hz), 32.4 (m), 30.1, 29.0, 24.8 (d, J = 2.2 Hz), 15.9 (d, J = 20.5 Hz). ³¹P{¹H} NMR (243 MHz, d₆-C₆D₆, 298 K): δ = 10.6. ¹¹B{¹H} NMR (193 MHz, d₆-C₆D₆, 298 K): δ = -13.4. HRESI(+)-MS: calcd. 320.2799 exptl. 320.2741 for C₂₀H₃₈BP [M]⁺.

2-(2-di-tert-butylphosphinoethyl)-1-boraadamantane (**4^{t-Bu}**; C₁₉H₃₆BP, 306 g/mol): 2-(2-chloroethyl)-1-boraadamantane (325 mg, 1.21 mmol) was reacted with LiP(*t*-Bu)₂ (184 mg, 1.21 mmol, 1 equiv.) according to the general procedure described above. The product was obtained as colorless crystals after




recrystallization from Et₂O (254 mg, 69%). Crystals suitable for X-ray diffraction were grown by

cooling a concentrated solution in Et₂O to -35 °C overnight. ¹H NMR (600 MHz, d₆-C₆D₆, 298 K): δ = 2.64 (m, 1H), 2.49 (m, 1H), 2.41 (m, 1H), 2.16 (m, 4H), 1.95 (m, 1H), 1.88 (m, 3H), 1.47 (m, 2H), 1.28 (m, 3H), 1.12 (m, 2H), 0.97 (dd, J = 11.7, 1.9 Hz, 18H, -P(*t*-Bu)₂). ¹³C{¹H} NMR (101 MHz, d₆-C₆D₆, 298 K): δ = 41.7 (d, J = 45.4 Hz), 35.6 (d, J = 10.4 Hz), 34.4, 33.2 (m), 29.9 (d, J = 2.6 Hz), 29.1 (d, J = 9.0 Hz), 28.9, 18.5 (d, J = 32.6 Hz). ³¹P{¹H} NMR (243 MHz, d₆-C₆D₆, 298 K): δ = 41.4. ¹¹B{¹H} NMR (193 MHz, d₆-C₆D₆, 298 K): δ = -9.6. HRESI(+)-MS: calcd. 306.2642 exptl. 306.2637 for C₁₉H₃₆BP [M]⁺.

3-Methoxy-7-(2-diphenylphosphinoethyl)-3-borabicyclo[3.3.1]non-6-ene


(6^{Ph}; C₂₃H₂₈BOP, 362 g/mol): In the glovebox, 3-methoxy-7-(2-bromoethyl)-3-borabicyclo[3.3.1]non-6-ene (507 mg, 1.97 mmol) was weighed into a 20 mL scintillation vial equipped with a stir bar and dissolved in 5 mL of THF



and precooled to -35 °C. To this solution, LiP(*t*-Bu)₂ (379 mg, 1.97 mmol, 1 equiv.) dissolved in 10 mL of THF was added dropwise, which resulted in a rapid decolorization. After stirring the mixture for 2 h, all volatiles were removed *in vacuo*, resulting in a cloudy oil. The mixture was extracted with *n*-hexane, filtered and the filtrate subsequently dried *in vacuo*, yielding again a cloudy oil. The procedure was repeated until a colorless oil (661 mg, 92%) was obtained. ¹H NMR (600 MHz, d₁-CDCl₃, 298 K): 7.42 (m, 10H, -PPh₂), 5.48 (m, 1H), 3.66 (s, 3H, -OMe), 2.47 (m, 2H), 2.35 (m, 1H), 2.14 (m, 2H), 2.03 (m, 2H), 1.78 (m, 1H), 1.66 (m, 2H), 1.09 (m, 1H), 1.00 (m, 1H), 0.88 (m, 1H). ¹³C{¹H} NMR (101 MHz, d₁-CDCl₃, 298 K): δ = 138.9 (t, J = 13.2 Hz), 134.1 (m), 132.8 (dd, J = 18.4, 11.1 Hz), 128.4 (m), 53.2, 37.5, 33.9 (d, J = 16.8 Hz), 32.7, 29.3, 27.5, 26.6 (d, J = 12.0 Hz), 25.0 (m). ³¹P{¹H} NMR (243 MHz, d₁-CDCl₃, 298 K): δ = -15.9. ¹¹B{¹H} NMR (193 MHz, d₁-CDCl₃, 298 K): δ = 55.2.


2-(1-di-phenylphosphinomethyl)-1-boraadamantane (7^{Ph}; C₂₆H₃₇B₂OP,

418 g/mol): 3-Methoxy-7-(2-diphenylphosphinoethyl)-3-borabicyclo[3.3.1]non-6-ene 6^{Ph} (564 mg, 1.56 mmol) was dissolved in 10 mL THF in a Schlenk-flask equipped with a stir bar and a septum. The mixture was cooled to 0 °C and BH₃·THF (3.12 mL, 3.12 mmol, 2 eq.) was



added dropwise via syringe. The septum is replaced by a reflux condenser and the reaction mixture was boiled under reflux conditions for 3 h. Subsequently, all volatiles were removed *in vacuo* and the residual solid was brought into a glovebox. There, the residue was washed three times with 5 mL of *n*-pentane each and further drying under reduced pressure yielded a colorless powder (530 mg, 81%). Crystals suitable for X-ray diffraction were grown by cooling a concentrated solution in THF to -35 °C overnight. **¹H NMR (600 MHz, d₈-THF, 298 K):** δ = 7.80 (m, 4H, -PPh₂), 7.42 (m, 6H, -PPh₂), 3.65 (m, 2H, THF), 2.64 (m, 1H), 2.14 (m, 2H), 2.01 (m, 1H), 1.81 (m, 2H, THF), 1.76 (m, 2H), 1.45 (m, 8H), 1.11 (m, 2H), 0.94 (m, 4H), 0.65 (m, 3H, -BH₃). **¹³C{¹H} NMR (151 MHz, d₈-THF, 298 K):** δ = 132.6 (d, J = 8.8 Hz, -PPh₂), 131.9 (d, J = 8.2 Hz, -PPh₂), 130.2 (dd, J = 45.3, 2.4 Hz, -PPh₂), 128.2 (d, J = 9.3 Hz, -PPh₂), 128.0 (d, J = 9.4 Hz), 67.3 (THF), 40.3 (d, J = 16.0 Hz), 35.5 (d, J = 1.4 Hz), 33.3 (m), 25.4 (THF), 24.7 (d, J = 20.0 Hz), 24.5 (d, J = 3.6 Hz). **³¹P{¹H} NMR (243 MHz, d₈-THF, 298 K):** δ = 16.4. **¹¹B{¹H} NMR (193 MHz, d₈-THF, 298 K):** δ = 10.6, -39.4 (-BH₃). **HRESI(+)-MS:** calcd. 387.2453 exptl. 387.2446 for C₂₄H₃₂B₂NP [M+CH₃CN (without THF)]⁺.


4-Dimethylaminopyridine adduct of 4^t-Bu (8^t-Bu-DMAP;
C₂₆H₄₆BN₂P, 428 g/mol): 2-(2-di-*tert*-butylphosphinoethyl)-1-



boraadamantane 4^t-Bu (18 mg, 0.06 mmol) was weighed into a 20 mL scintillation vial equipped with a stir bar and dissolved in 2 mL of toluene. To this solution, 4-dimethylaminopyridine (7 mg, 0.06 mmol, 1 eq.) dissolved in 2 mL of toluene was added. After stirring the mixture for 10 mins, all volatiles were removed *in vacuo* and the oily residue washed with 2 mL of cold pentane. Further drying with reduced pressure resulted in a colorless powder (23 mg, 90%). Crystals suitable for X-ray diffraction were grown by slowly evaporating a solution in *n*-pentane overnight. **¹H NMR (600 MHz, d₆-C₆D₆, 298 K):** δ = 7.94 (m, 2H, DMAP), 5.58 (m, 2H, DMAP), 2.89 (m, 2H), 2.68 (m, 1H), 2.43 (m, 1H), 2.33 (m, 2H), 2.27 (m, 1H), 2.21 (m, 2H), 1.99 (m, 2H), 1.94 (s, 6H, -NMe₂), 1.77 (m, 1H), 1.48 (m, 1H), 1.31 (m, 2H), 1.20 (m, 2H), 1.11 (m, 1H), 1.11 (dd, J = 48.1, 10.3 Hz, 18H, -P(*t*-Bu)₂). **¹³C{¹H} NMR (101 MHz, d₆-C₆D₆, 298 K):** δ = 153.8 (m, DMAP), 143.4 (DMAP), 105.9 (DMAP), 42.6, 41.6, 37.8 (DMAP), 35.3, 34.6, 33.7, 33.2, 31.3 (d, J = 23.4 Hz), 30.9 (dd, J = 28.8, 23.8

Hz), 29.7 (t, $J = 13.6$ Hz), 21.5 (d, $J = 21.8$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (243 MHz, $\text{d}_6\text{-C}_6\text{D}_6$, 298 K): $\delta = 28.8$. $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, $\text{d}_6\text{-C}_6\text{D}_6$, 298 K): $\delta = -4.6$. HRESI(+)-MS: calcd. 429.3564 exptl. 429.3565 for $\text{C}_{26}\text{H}_{47}\text{BN}_2\text{P}$ $[\text{M}+\text{H}]^+$.


Reaction of $4^{\text{t-Bu}}$ with HNEt_2 ($8^{\text{t-Bu}}\text{-HNEt}_2$; $\text{C}_{23}\text{H}_{47}\text{BNP}$, 379 g/mol): 2-(2-di-*tert*-butylphosphinoethyl)-1-boraadamantane $4^{\text{t-Bu}}$ (10 mg, 0.032 mmol) was weighed into a 20 mL scintillation vial equipped



with a stir bar and dissolved in 500 μL of C_6D_6 . To this solution, HNEt_2 (3.31 μL , 0.032 mmol, 1 eq.) was added, giving a pale-yellow solution after 5 mins, that was characterized as a 1:0.37 mixture of $4^{\text{t-Bu}}\text{:}8^{\text{t-Bu}}\text{-HNEt}_2$. Addition of excess HNEt_2 (86 μL , 0.83 mmol, 26 eq.) to $4^{\text{t-Bu}}$ (10 mg, 0.032 mmol) provides a 1:5.7 mixture of $4^{\text{t-Bu}}\text{:}8^{\text{t-Bu}}\text{-HNEt}_2$. Upon application of vacuum, exclusive formation of ring-closed $4^{\text{t-Bu}}$ is observed, confirming HNEt_2 lability. ^1H NMR (600 MHz, $\text{d}_6\text{-C}_6\text{D}_6$, 298 K, select signals): $\delta = 3.65$ (m, 1H, $\text{CH}(\text{HNEt}_2)$), 3.43 (m, 1H, $\text{CH}(\text{HNEt}_2)$), 2.02 (m, 2H, $\text{CH}(\text{HNEt}_2)$ by $^1\text{H}\text{-}^1\text{H}$ COSY), 1.23 (m, 6H, $\text{CH}_3(\text{HNEt}_2)$ by $^1\text{H}\text{-}^1\text{H}$ COSY). Free HNEt_2 : ($\delta = 2.47$ (4H, q, $^3J_{\text{H,H}} = 7.3$ Hz), 0.99 (6H, t, $^3J_{\text{H,H}} = 7.3$ Hz). $^{31}\text{P}\{^1\text{H}\}$ NMR (243 MHz, $\text{d}_6\text{-C}_6\text{D}_6$, 298 K): $\delta = 41.4$ ($4^{\text{t-Bu}}$), 29.5 ($8^{\text{t-Bu}}\text{-HNEt}_2$). $^{11}\text{B}\{^1\text{H}\}$ NMR (193 MHz, $\text{d}_6\text{-C}_6\text{D}_6$, 298 K): $\delta = -4.0$ ($8^{\text{t-Bu}}\text{-HNEt}_2$), -9.6 ($4^{\text{t-Bu}}$). HRESI(+)-MS: calcd. 307.2726 exptl. 307.2720 for $\text{C}_{19}\text{H}_{37}\text{BP}$ $[\text{M}+\text{H}\text{-HNEt}_2]^+$.

Gold complex of $8^{\text{t-Bu}}\text{-DMAP}$ ($9^{\text{t-Bu}}$; $\text{C}_{26}\text{H}_{46}\text{AuBCIN}_2\text{P}$, 660 g/mol):


$[\text{AuCl}(\text{SMe}_2)]$ (20 mg, 0.07 mmol) was weighed into a 20 mL scintillation vial equipped with a stir bar and dissolved in 2 mL of *ortho*-difluorobenzene. To this solution, freshly prepared $8^{\text{t-Bu}}\text{-DMAP}$ (29 mg, 0.07 mmol, 1 eq.) dissolved in 2



mL of *ortho*-difluorobenzene was added. After stirring the mixture for 2 h, a dark precipitate has formed and the mixture was filtered through celite, resulting in a clear, colorless solution. All volatiles were removed *in vacuo* and the residue subsequently washed with 2×2 mL of cold pentane. Further drying with reduced pressure resulted in a colorless powder (36 mg, 78%).

Crystals suitable for X-ray diffraction were grown by cooling down a concentrated solution in Et₂O to -35 °C overnight. ¹H NMR (600 MHz, d₆-C₆D₆, 298 K): δ = 8.01 (m, 2H, DMAP), 6.11 (m, 2H, DMAP), 2.85 (m, 2H), 2.43 (m, 1H), 2.37 (m, 1H), 2.28 (s, 6H, DMAP), 2.23 (m, 3H), 2.09 (m, 1H), 1.99 (m, 1H), 1.94 (m, 2H), 1.88 (m, 1H), 1.43 (m, 2H), 1.34 (m, 1H), 1.23 (m, 2H), 1.09 (m, 2H), 0.86 (d, *J* = 14.4 Hz, 9H, -P(*t*-Bu)₂), 0.76 (d, *J* = 14.4 Hz, 9H, -P(*t*-Bu)₂). ¹³C{¹H} NMR (101 MHz, d₆-C₆D₆, 298 K): δ = 154.4, 142.9, 106.9, 42.3, 41.3, 38.3, 34.4 (m), 33.5, 32.9, 31.4 (d, *J* = 1.6 Hz), 29.1 (d, *J* = 4.8 Hz), 28.7 (d, *J* = 4.9 Hz), 20.4 (d, *J* = 26.2 Hz). ³¹P{¹H} NMR (243 MHz, d₆-C₆D₆, 298 K): δ = 75.1. ¹¹B{¹H} NMR (193 MHz, d₆-C₆D₆, 298 K): δ = -5.4. HRESI(+)-MS: calcd. 660.2840 exptl. 660.2828 for C₂₆H₄₆AuBCIN₂P [M]⁺.

Platinum complex of 8^{*t*}-Bu-DMAP (10^{*t*}-Bu; C₅₄H₉₈B₂N₄P₂Pt, 1082 g/mol): [Pt(Me)₂(COD)] (20 mg, 0.06 mmol) was weighed into a 25 mL Schlenk bomb equipped with a stir bar and dissolved in 2 mL of toluene. To this solution, freshly prepared 8^{*t*}-Bu-DMAP (50 mg, 0.12 mmol, 2 eq.) dissolved in 10 mL of toluene was added. Subsequently, the mixture was



heated to 80 °C for 16 h which led to the precipitation of a colorless solid. The supernatant was decanted and the remaining solid washed with 2 x 2 mL of *n*-pentane. Further drying with reduced pressure resulted in a colorless powder (23 mg, 35%). Crystals suitable for X-ray diffraction were grown by vapor diffusion of *n*-hexane onto a concentrated solution in THF over 3 days. ¹H NMR (600 MHz, d₈-THF, 298 K): δ = 8.02 (m, 4H, DMAP), 6.70 (m, 4H, DMAP), 3.11 (s, 12H, DMAP), 2.19 (m, 4H), 2.07 (m, 3H), 1.81 (m, 4H), 1.62 (m, 6H), 1.41 (d, *J* = 12.4 Hz, 4H), 1.36 – 1.13 (br, 43H, -P(*t*-Bu)₂), 0.93 (m, 2H), 0.77 (s, 4H), 0.58 (m, 3H), -0.18 (br, 5H). ¹³C{¹H} NMR (101 MHz, d₈-THF, 298 K): δ = 155.0, 143.4, 106.5, 66.3, 42.1, 41.0, 38.3, 34.7, 33.2, 32.8, 31.5, 30.7, 30.2, 24.3, 22.5, 13.4. ³¹P{¹H} NMR (243 MHz, d₈-THF, 298 K): δ = 33.8 (¹*J*(¹⁹⁵Pt, ³¹P) = 3012 Hz). ¹¹B{¹H} NMR (193 MHz, d₈-THF, 298 K): δ = -4.7. HRESI(+)-MS: calcd. 1066,6865 exptl. 1066.6876 for C₅₃H₉₅B₂N₄P₂Pt [M-CH₃]⁺.

Multinuclear NMR Data:

Figure S1: 2^{Ph} , ^1H NMR, $\text{d}_1\text{-CDCl}_3$, 600 MHz, 298 K.




Figure S2: 2^{Ph} , $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 243 MHz, 298 K.




Figure S3: 2^{Ph} , $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 193 MHz, 298 K.




Figure S4: 2^{Ph} , $^{13}\text{C}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 101 MHz, 298 K.




Figure S5: 4^{Ph}, ¹H NMR, d₁-CDCl₃, 600 MHz, 298 K.




Figure S6: 4^{Ph}, ³¹P{¹H} NMR, d₁-CDCl₃, 243 MHz, 298 K.




Figure S7: 4^{Ph} , $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 193 MHz, 298 K.




Figure S8: 4^{Ph} , $^{13}\text{C}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 101 MHz, 298 K.




Figure S9: 2^{t-Bu}, ¹H NMR, d₆-C₆D₆, 600 MHz, 298 K. * denotes traces of THF.




Figure S10: 2^{t-Bu}, ³¹P{¹H} NMR, d₆-C₆D₆, 243 MHz, 298 K.




Figure S11: 2^{t-Bu}, ¹¹B{¹H} NMR, d₆-C₆D₆, 193 MHz, 298 K. * denotes unknown impurity.




Figure S12: 2^{t-Bu}, ¹³C{¹H} NMR, d₆-C₆D₆, 101 MHz, 298 K. * denotes traces of THF.




Figure S13: 4^t-Bu, ¹H NMR, d₆-C₆D₆, 600 MHz, 298 K. * denotes traces of THF.




Figure S14: 4^t-Bu, ³¹P{¹H} NMR, d₆-C₆D₆, 243 MHz, 298 K.




Figure S15: 4^t-Bu, ¹¹B{¹H} NMR, d₆-C₆D₆. 193 MHz, 298 K. * denotes unknown impurity.




Figure S16: 4^t-Bu, ¹³C{¹H} NMR, d₆-C₆D₆, 101 MHz, 298 K. * denotes traces of THF.




Figure S17: 6^{Ph} , ^1H NMR, $\text{d}_1\text{-CDCl}_3$, 600 MHz, 298 K. * denotes residual n -pentane.




Figure S18: 6^{Ph} , $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 243 MHz, 298 K. * denotes trace HPPH_2 .




Figure S19: 6^{Ph} , $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 193 MHz, 298 K.




Figure S20: 6^{Ph} , $^{13}\text{C}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 101 MHz, 298 K. * denotes residual *n*-pentane.




Figure S21: 7^{Ph} , ^1H NMR, d_8 -THF, 600 MHz, 298 K. * denotes traces of silicon grease.




Figure S22: 7^{Ph} , $^{31}\text{P}\{^1\text{H}\}$ NMR, d_8 -THF, 243 MHz, 298 K.




Figure S23: 7^{Ph} , $^{11}\text{B}\{^1\text{H}\}$ NMR, d_8 -THF, 193 MHz, 298 K.




Figure S24: 7^{Ph} , $^{13}\text{C}\{^1\text{H}\}$ NMR, d_8 -THF, 101 MHz, 298 K.




Figure S25: 8^t-Bu-DMAP, ¹H NMR, d₆-C₆D₆, 600 MHz, 298 K.




Figure S26: 8^t-Bu-DMAP, ³¹P{¹H} NMR, d₆-C₆D₆, 243 MHz, 298 K.




Figure S27: 8^t-Bu-DMAP, ¹¹B{¹H} NMR, d₆-C₆D₆, 193 MHz, 298 K.




Figure S28: 8^t-Bu-DMAP, ¹³C{¹H} NMR, d₆-C₆D₆, 101 MHz, 298 K.




Figure S29: 8^t-Bu-HNEt₂, ¹H NMR, d₆-C₆D₆, 600 MHz, 298 K.




Figure S30: 8^t-Bu-HNEt₂, ³¹P{¹H} NMR, d₆-C₆D₆, 243 MHz, 298 K. Top: equimolar amounts 4^t-Bu : HNEt₂; Middle: 26 eq. HNEt₂; Bottom: remaining material after all volatiles have been removed.




Figure S31: 8^{t-Bu}-HNEt₂, ¹¹B{¹H} NMR, d₆-C₆D₆, 193 MHz, 298 K.




Figure S32: 9^{t-Bu}, ¹H NMR, d₆-C₆D₆, 600 MHz, 298 K.




Figure S33: $9^{t\text{-Bu}}$, $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K. $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 193 MHz, 298 K. * denotes unknown impurity.




Figure S34: $9^{t\text{-Bu}}$, $9^{t\text{-Bu}}$, $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K.




Figure S35: $9^{t\text{-Bu}}$, $^{13}\text{C}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 101 MHz, 298 K.




Figure S36: $10^{t\text{-Bu}}$, ^1H NMR, $\text{d}_8\text{-THF}$, 600 MHz, 298 K.




Figure S37: 10^t-Bu , $^{11}\text{B}\{^1\text{H}\}$ NMR, $d_8\text{-THF}$, 193 MHz, 298 K.




Figure S38: 10^t-Bu , $^{31}\text{P}\{^1\text{H}\}$ NMR, $d_8\text{-THF}$, 243 MHz, 298 K.





Figure S39: 10^t-Bu , $^{13}\text{C}\{^1\text{H}\}$ NMR, $d_8\text{-THF}$, 101 MHz, 298 K.



Additional reactions:

i. Reaction of 4^{t-Bu} with CO₂ and H₂.

In a typical experiment, 4^{t-Bu} (30 mg, 0.098 mmol) was dissolved in 20 mL *n*-pentane and placed in a Schlenk bomb. The solution was degassed with three freeze-pump-thaw cycles and subsequently an atmosphere of CO₂ or H₂ was added. After stirring overnight, an aliquot was analyzed by ³¹P{¹H} NMR spectroscopy indicating no reaction (**Figures S40 and S41**).




Figure S40: Reaction of $4^{t\text{-Bu}}$ with CO_2 , $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K.




Figure S41: Reaction of $4^{t\text{-Bu}}$ with H_2 , $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K.

ii. Reaction of $4^{t\text{-Bu}}$ with Lewis Bases.

Additional Lewis bases of different donor strength were added to $4^{t\text{-Bu}}$ to investigate potential for P-B ring-opening.

Reaction:

1) $4^{t\text{-Bu}}$ + pyridine \rightarrow ring opening

10 mg of $4^{t\text{-Bu}}$ was weighed into a 20 mL scintillation vial and dissolved in 500 μL C_6D_6 . 1 equivalent of pyridine was added. Ring-opening was concluded by $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy (**Figure S42**).

2) $4^{t\text{-Bu}}$ + DMSO \rightarrow no reaction

10 mg of $4^{t\text{-Bu}}$ was weighed into a 20 mL scintillation vial and dissolved in 500 μL C_6D_6 . 1 equivalent of DMSO- d_6 was added. No reaction was observed by $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy (**Figure S43**).

3) $4^{t\text{-Bu}}$ + DMF \rightarrow no reaction

10 mg of $4^{t\text{-Bu}}$ was weighed into a 20 mL scintillation vial and dissolved in 500 μL C_6D_6 . 1 equivalent of DMF was added. No reaction was observed by $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy (**Figure S44**).

4) $4^{t\text{-Bu}}$ + NEt_3 \rightarrow no reaction

10 mg of $4^{t\text{-Bu}}$ was weighed into a 20 mL scintillation vial and dissolved in 500 μL C_6D_6 . 1 equivalent of NEt_3 was added. No reaction was observed by $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy (**Figure S45**).




Figure S42: Reaction of $4^{t\text{-Bu}}$ with pyridine, left: $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 193 MHz, 298 K.




Figure S43: Reaction of $4^{t\text{-Bu}}$ with DMSO, left: $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 193 MHz, 298 K.




Figure S44: Reaction of 4-*t*-Bu with DMF, left: $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 193 MHz, 298 K.




Figure S45: Reaction of 4-*t*-Bu with NEt_3 , left: $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 193 MHz, 298 K.

iii. Reaction of $4^{t\text{-Bu}}$ with Lewis Acids or a Hydride Source.

Ring-opening reactions were attempted by treating $4^{t\text{-Bu}}$ with acids: $[\text{H}(\text{Et}_2\text{O})_2]\text{B}(\text{C}_6\text{F}_5)_4$, $[\text{AuCl}(\text{SMe}_2)]$, or a hydride source, $\text{Li}[\text{HBET}_3]$.

Reaction:

1) $4^{t\text{-Bu}} + [\text{H}(\text{Et}_2\text{O})_2]\text{B}(\text{C}_6\text{F}_5)_4 \rightarrow$ ring-opening

10 mg of $4^{t\text{-Bu}}$ was weighed into a 20 mL scintillation vial and dissolved in 500 μL fluorobenzene. 1 equivalent of $[\text{H}(\text{Et}_2\text{O})_2]\text{B}(\text{C}_6\text{F}_5)_4$ was added. Volatiles were removed *in vacuo* and the sample was redissolved in THF- d_8 . A main phosphonium species along with several side products was observed (**Figures S46 and S47**).

2) $4^{t\text{-Bu}} + [\text{AuCl}(\text{SMe}_2)] \rightarrow$ multiple products

21 mg of $4^{t\text{-Bu}}$ was weighed into a 20 mL scintillation vial and dissolved in 2 mL of *ortho*-difluorobenzene (*o*-DFB). 1 equivalent of $[\text{AuCl}(\text{SMe}_2)]$ dissolved in 2 mL of *o*-DFB was added. The mixture was stirred for 2 h and filtered through celite. All volatiles were removed *in-vacuo* and the residual solid dissolved in C_6D_6 (**Figure S48**).

3) $4^{t\text{-Bu}} + \text{LiHBET}_3 \rightarrow$ no reaction

$4^{t\text{-Bu}}$ (10 mg, X mmol) was weighed into a 20 mL scintillation vial and dissolved in 500 μL THF. 1 equivalent of LiBHEt_3 was added. No reaction was observed by $^{31}\text{P}\{^1\text{H}\}$ NMR spectroscopy (**Figure S49**).




Figure S46: Reaction of 4^t-Bu with [H(Et₂O)₂][B(C₆F₅)₄], left: ³¹P{¹H} NMR, d₈-THF, 243 MHz, 298 K; middle: ³¹P NMR, d₈-THF, 162 MHz, 298 K δ = 53 (d, J = 451 Hz, P-H); right: ¹¹B{¹H} NMR, d₈-THF, 193 MHz, 298 K.




Figure S47: Reaction of 4^t-Bu with [H(Et₂O)₂][B(C₆F₅)₄], top: ¹H{³¹P} NMR, d₈-THF, 243 MHz, 298 K; bottom: ¹H NMR, d₈-THF, 193 MHz, 298 K. δ = 5.54 (d, J = 451 Hz, P-H)




Figure S48: Reaction of $4^{t\text{-Bu}}$ with $[\text{AuCl}(\text{SMe}_2)]$, $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K.




Figure S49: Reaction of $4^{t\text{-Bu}}$ with $\text{Li}[\text{HBEt}_3]$, left: $^{31}\text{P}\{^1\text{H}\}$ NMR, THF, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, THF, 193 MHz, 298 K.

iv. Attempts to deprotect 7^{Ph}

Reactions carried out to deprotect 7^{Ph} (either at phosphorus or boron) included treatment with DABCO, B(C₆F₅)₃ (BCF), [H(Et₂O)₂][B(C₆F₅)₄], NaOtBu, and Verkade Base. These reactions were not clean and in the case of base addition, often yielded base-coordinated boraadamantanes.


Reaction:



20 mg of 7^{Ph} was weighed into a 20 mL scintillation vial and dissolved in 2 mL of toluene. 1 equivalent of DABCO was added. After stirring for 2 h, all volatiles were removed *in-vacuo*. Afterwards, the residual material was dissolved in C₆D₆ (**Figure S50**).



10 mg of 7^{Ph} was weighed into a 20 mL scintillation vial and dissolved in 500 μL of CDCl₃. 1 equivalent of BCF was added (**Figure S51**).



20 mg of 7^{Ph} was weighed into a 20 mL scintillation vial and dissolved in 4 mL of Et₂O. 1 equivalent of [H(Et₂O)₂][B(C₆F₅)₄] was added. The mixture was stirred for 2 h, filtered, and evaporated. The remaining material was dissolved in CDCl₃ (**Figure S52**).



20 mg of 7^{Ph} was weighed into a 20 mL scintillation vial and dissolved in 500 μL THF. 1 equivalent of NaOtBu was added (**Figure S53**).



20 mg of 7^{Ph} was weighed into a 20 mL scintillation vial and dissolved in 500 μL C₆D₆. 1 equivalent of Verkade's Base was added (**Figure S54**).




Figure S50: Reaction of 7^{Ph} with DABCO, left: $^{31}\text{P}\{^1\text{H}\}$ NMR, $d_6\text{-C}_6\text{D}_6$, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, $d_6\text{-C}_6\text{D}_6$, 193 MHz, 298 K.




Figure S51: Reaction of 7^{Ph} with BCF, left: $^{31}\text{P}\{^1\text{H}\}$ NMR, $d_1\text{-CDCl}_3$, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, $d_1\text{-CDCl}_3$, 193 MHz, 298 K.




Figure S52: Reaction of 7^{Ph} with $[\text{H}(\text{Et}_2\text{O})_2]\text{B}(\text{C}_6\text{F}_5)_4$, left: $^{31}\text{P}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, $\text{d}_1\text{-CDCl}_3$, 193 MHz, 298 K.




Figure S53: Reaction of 7^{Ph} with NaOtBu , left: $^{31}\text{P}\{^1\text{H}\}$ NMR, THF, 243 MHz, 298 K; right: $^{11}\text{B}\{^1\text{H}\}$ NMR, THF, 193 MHz, 298 K.




Figure S54: Reaction of **7^{Ph}** with Verkade's base, left: ³¹P{¹H} NMR, d₆-C₆D₆, 243 MHz, 298 K; right: ¹¹B{¹H} NMR, d₆-C₆D₆, 193 MHz, 298 K.




Figure S55 Proposed hydroboration-isomerization mechanism for 1-boraadamantane formation.^[2]

X-Ray Crystallography:

Crystal data were collected with MoK α radiation on a Bruker Kappa Axis Apex2 diffractometer at Western University and on a Bruker VENTURE Dual Source diffractometer at McMaster University. All crystals were mounted on a MiTeGen loop with a small amount of Paratone N oil. Frame integration, scaling and absorption correction were performed using SAINT and SADABS integrated in Apex4.^[3] The structures were solved with the ShelXT^[4] structure solution program using intrinsic phasing and refined with the ShelXL^[5] refinement package using least squares on weighted F² values for all reflections using OLEX2.^[6] CCDC 2355758, 2355760, 2355759, 2355761, 2355762, 2355763, 2355764, and 2355765 contain the supplementary crystallographic data for this paper. These data are provided free of charge by The Cambridge Crystallographic Data Centre.

Table S1. Crystallographic data

	2 ^{Ph}	4 ^{Ph}	2 ^{t-Bu}	4 ^{t-Bu}	7 ^{Ph}
CCDC number	2355758	2355760	2355759	2355761	2355762
empirical formula	C ₂₄ H ₃₀ BP	C ₂₃ H ₂₈ BP	C ₂₀ H ₃₈ BP	C ₁₉ H ₃₆ BP	C ₂₆ H ₃₇ B ₂ OP
formula weight	360.26	346.23	320.28	306.26	418.14
temperature [K]	100.0	100.00	110.15	100.00	100.00
crystal system	triclinic	orthorhombic	monoclinic	orthorhombic	triclinic
space group	<i>P</i> -1	<i>P</i> 2 ₁ 2 ₁	<i>P</i> 2 ₁ / <i>c</i>	<i>P</i> bca	<i>P</i> -1
<i>a</i> [Å]	9.6433(4)	7.1446(8)	13.620(8)	15.2898(7)	9.1755(6)
<i>b</i> [Å]	10.8253(5)	12.0021(13)	10.375(6)	12.3183(5)	11.3395(7)
<i>c</i> [Å]	10.9474(5)	21.825(2)	13.264(7)	19.1817(8)	12.5538(8)
α [°]	75.970(2)	90	90	90	78.769(2)
β [°]	65.639(2)	90	93.932(13)	90	77.719(3)
γ [°]	70.947(2)	90	90	90	67.258(2)
volume [Å ³]	976.29(8)	1871.5(4)	1869.9(19)	3612.8(3)	1167.84(13)
<i>Z</i>	2	4	4	8	2
ρ_{calcd} [g · cm ⁻³]	1.225	1.229	1.138	1.126	1.189
μ [mm ⁻¹]	0.146	0.149	0.143	0.146	0.133
<i>F</i> (000)	388.0	744.0	712.0	1360.0	452.0
dimension [mm]	0.323 × 0.209 × 0.172	0.475 × 0.122 × 0.093	0.34 × 0.322 × 0.075	0.394 × 0.305 × 0.22	0.404 × 0.24 × 0.148
radiation	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)
2 θ range for data collection/°	5.06 to 56.684	3.872 to 52.818	6.662 to 72.786	4.748 to 52.776	3.926 to 56.654
index ranges	-12 ≤ <i>h</i> ≤ 12, -14 ≤ <i>k</i> ≤ 14, -14 ≤ <i>l</i> ≤ 14	-5 ≤ <i>h</i> ≤ 8, -13 ≤ <i>k</i> ≤ 15, -27 ≤ <i>l</i> ≤ 27	-22 ≤ <i>h</i> ≤ 22, -17 ≤ <i>k</i> ≤ 17, -22 ≤ <i>l</i> ≤ 22	-19 ≤ <i>h</i> ≤ 18, -11 ≤ <i>k</i> ≤ 15, -23 ≤ <i>l</i> ≤ 23	-12 ≤ <i>h</i> ≤ 12, -15 ≤ <i>k</i> ≤ 15, -16 ≤ <i>l</i> ≤ 16
reflections collected	39925	13486	117764	37409	44609
independent reflections	4846 [<i>R</i> _{int} = 0.0351, <i>R</i> _{sigma} = 0.0198]	3708 [<i>R</i> _{int} = 0.0512, <i>R</i> _{sigma} = 0.0608]	9085 [<i>R</i> _{int} = 0.0689, <i>R</i> _{sigma} = 0.0332]	3683 [<i>R</i> _{int} = 0.0436, <i>R</i> _{sigma} = 0.0223]	5809 [<i>R</i> _{int} = 0.0389, <i>R</i> _{sigma} = 0.0232]
data/restraints/parameters	4846/0/235	3708/156/308	9085/0/351	3683/0/196	5809/0/283
goodness-of-fit on <i>F</i> ²	1.046	1.053	1.039	1.034	1.041
final <i>R</i> indexes [<i>I</i> > 2 σ (<i>I</i>)]	<i>R</i> ₁ = 0.0324, <i>wR</i> ₂ = 0.0857	<i>R</i> ₁ = 0.0440, <i>wR</i> ₂ = 0.0855	<i>R</i> ₁ = 0.0364, <i>wR</i> ₂ = 0.0877	<i>R</i> ₁ = 0.0462, <i>wR</i> ₂ = 0.1178	<i>R</i> ₁ = 0.0376, <i>wR</i> ₂ = 0.0975
final <i>R</i> indexes [all data]	<i>R</i> ₁ = 0.0345, <i>wR</i> ₂ = 0.0875	<i>R</i> ₁ = 0.0637, <i>wR</i> ₂ = 0.0932	<i>R</i> ₁ = 0.0558, <i>wR</i> ₂ = 0.0973	<i>R</i> ₁ = 0.0485, <i>wR</i> ₂ = 0.1203	<i>R</i> ₁ = 0.0428, <i>wR</i> ₂ = 0.1013
largest diff. peak/hole [e Å ⁻³]	0.35/-0.25	0.21/-0.33	0.42/-0.24	0.56/-0.39	0.41/-0.20

	8^t-Bu-DMAP	9^t-Bu	10^t-Bu
CCDC number	2355763	2355764	2355765
empirical formula	C ₂₆ H ₄₆ BN ₂ P	C ₂₉ H _{53.5} AuBCIN ₂ O _{0.75} P	C ₅₆ H ₁₀₂ B ₂ N ₄ O _{0.5} P ₂ Pt
formula weight	428.43	716.43	1118.06
temperature [K]	110.00	110	110
crystal system	triclinic	triclinic	triclinic
space group	<i>P</i> -1	<i>P</i> -1	<i>P</i> -1
<i>a</i> [Å]	11.1805(5)	7.1927(4)	10.6781(5)
<i>b</i> [Å]	11.2066(5)	11.9175(6)	10.9251(5)
<i>c</i> [Å]	11.5832(5)	19.1310(10)	12.9656(6)
α [°]	69.782(2)	78.6195(18)	101.270(3)
β [°]	80.362(2)	86.0612(18)	98.789(3)
γ [°]	74.668(2)	86.5573(18)	90.250(3)
volume [Å ³]	1308.78(10)	1602.04(15)	1465.06(12)
<i>Z</i>	2	2	1
ρ_{calcd} [g · cm ⁻³]	1.087	1.485	1.267
μ [mm ⁻¹]	0.120	4.747	2.487
F(000)	472.0	727.0	588.0
dimension [mm]	0.24 × 0.13 × 0.102	0.387 × 0.122 × 0.072	0.187 × 0.117 × 0.117
radiation	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)	MoK α (λ = 0.71073)
2 θ range for data collection/°	3.76 to 52.812	2.176 to 61.286	6.158 to 51.658
index ranges	-13 ≤ <i>h</i> ≤ 13, -14 ≤ <i>k</i> ≤ 14, -14 ≤ <i>l</i> ≤ 14	-10 ≤ <i>h</i> ≤ 10, -17 ≤ <i>k</i> ≤ 17, -27 ≤ <i>l</i> ≤ 27	-13 ≤ <i>h</i> ≤ 13, -13 ≤ <i>k</i> ≤ 13, -15 ≤ <i>l</i> ≤ 15
reflections collected	88793	100956	91063
independent reflections	5354 [<i>R</i> _{int} = 0.0608, <i>R</i> _{sigma} = 0.0212]	9843 [<i>R</i> _{int} = 0.0685, <i>R</i> _{sigma} = 0.0344]	5569 [<i>R</i> _{int} = 0.0900, <i>R</i> _{sigma} = 0.0338]
data/restraints/parameters	5354/0/279	9843/67/391	5569/40/340
goodness-of-fit on <i>F</i> ²	1.047	1.040	1.053
final <i>R</i> indexes [<i>I</i> > 2 σ (<i>I</i>)]	<i>R</i> ₁ = 0.0389, <i>wR</i> ₂ = 0.0985	<i>R</i> ₁ = 0.0314, <i>wR</i> ₂ = 0.0630	<i>R</i> ₁ = 0.0371, <i>wR</i> ₂ = 0.0924
final <i>R</i> indexes [all data]	<i>R</i> ₁ = 0.0483, <i>wR</i> ₂ = 0.1065	<i>R</i> ₁ = 0.0406, <i>wR</i> ₂ = 0.0660	<i>R</i> ₁ = 0.0375, <i>wR</i> ₂ = 0.0927
largest diff. peak/hole [e Å ⁻³]	0.35/-0.30	2.31/-2.12	1.35/-2.29

$$R1 = \frac{\sum ||F_o| - |F_c||}{\sum |F_o|}; wR2 = \left[\frac{\sum (w(F_o^2 - F_c^2)^2)}{\sum w(F_o^2)^2} \right]^{1/2}$$

Computational Details:

All calculations were performed using version 5.0.3 of the ORCA computational package^[7] and were run on the Graham cluster maintained by Compute Canada. All geometry optimizations and frequency calculations were performed at the B3LYP-D3(BJ)/def2-TZVPP level of theory.^[8] The RIJCOSX approximation was used to enhance computational efficiency, along with the auxiliary basis *def2/J*.^[9] Convergence criteria were met using the *defgrid2* integral grid size. Frequency calculations (*Freq*) were performed to confirm that each optimized geometry was a true minimum indicated by the absence of imaginary frequencies. Single-point calculations were performed at the B3LYP-D3(BJ)/def2-TZVPP level of theory on optimized geometries. For selected compounds, the implicit solvation model CPCM (as integrated in ORCA) was applied with a dielectric constant of $\epsilon = 4.9$ (corresponds to CH_2Cl_2).^[10]

Table S2. Energetic data calculated at B3LYP-D3(BJ)/def2-TZVPP level of theory.

Compound	Total thermal energy in E_h	Total Enthalpy in E_h	Gibbs Free Energy at 298.15 K in E_h
2 ^{Ph} open	-1298.132375	-1298.131431	-1298.20445
4 ^{Ph} open	-1258.858898	-1258.857954	-1258.927612
7 ^{Ph} open	-1219.591419	-1219.590475	-1219.656709
2 ^{Ph} closed	-1298.163381	-1298.162437	-1298.231912
4 ^{Ph} closed	-1258.887342	-1258.886398	-1258.953857
7 ^{Ph} closed	-1219.583492	-1219.582548	-1219.648487
2 ^{t-Bu} open	-1150.474777	-1150.473832	-1150.548461
4 ^{t-Bu} open	-1111.200382	-1111.199438	-1111.270964
7 ^{t-Bu} open	-1071.926218	-1071.925274	-1071.993516
2 ^{t-Bu} closed	-1150.510798	-1150.509854	-1150.579224
4 ^{t-Bu} closed	-1111.230386	-1111.229442	-1111.297579
7 ^{t-Bu} closed	-1071.922716	-1071.921772	-1071.988395
BH ₃ -THF	-258.8931223	-258.8921781	-258.9302425
7 ^{Ph} + BH ₃ -THF	-1478.536015	-1478.535071	-1478.616828
7 ^{t-Bu} + BH ₃ -THF	-1330.8777	-1330.876756	-1330.958927
CO ₂	-188.57469	-188.5737459	-188.5979947
4 ^{Ph} + CO ₂	-1447.438927	-1447.437982	-1447.511893
7 ^{Ph} + CO ₂	-1408.175597	-1408.174653	-1408.245796
4 ^{t-Bu} + CO ₂	-1299.788251	-1299.787306	-1299.862082
7 ^{t-Bu} + CO ₂	-1260.528063	-1260.527119	-1260.598778
H ₂	-1.1611087	-1.16016449	-1.17495694
4 ^{Ph} + H ₂	-1260.004628	-1260.003684	-1260.072158
7 ^{Ph} + H ₂	-1220.734008	-1220.733064	-1220.799286
4 ^{t-Bu} + H ₂	-1112.355965	-1112.35502	-1112.424591
7 ^{t-Bu} + H ₂	-1073.080941	-1073.079997	-1073.147424

BAd	-376.5394094	-376.5384651	-376.577854
PPh ₂ Me	-844.2242627	-844.2233185	-844.2754205
PPh ₂ Et	-883.4975519	-883.4966076	-883.5521933
PPh ₂ Pr	-922.7725947	-922.7716505	-922.8296257
P <i>t</i> -Bu ₂ Me	-696.5688826	-696.5679384	-696.6206629
P <i>t</i> -Bu ₂ Et	-735.8384761	-735.8375319	-735.8930923
P <i>t</i> -Bu ₂ Pr	-775.1130585	-775.1121143	-775.1704333
BAd + PPh ₂ Me	-1220.802699	-1220.801755	-1220.87029
BAd + PPh ₂ Et	-1260.076332	-1260.075388	-1260.146689
BAd + PPh ₂ Pr	-1299.350284	-1299.349339	-1299.42256
BAd + P <i>t</i> -Bu ₂ Me	-1073.144962	-1073.144017	-1073.21247
BAd + P <i>t</i> -Bu ₂ Et	-1112.413016	-1112.412072	-1112.483126
BAd + P <i>t</i> -Bu ₂ Pr	-1151.68855	-1151.687606	-1151.761541

Table S3. Energetic data for solvated molecules calculated at B3LYP-D3(BJ)/def2-TZVPP level of theory with implicit solvation model (CPCM, $\epsilon = 4.9$).

Compound	Total thermal energy in E_h	Total Enthalpy in E_h	Gibbs Free Energy at 298.15 K in E_h
7 ^{Ph} open	-1219.599689	-1219.598745	-1219.665123
4 ^{Ph} closed	-1258.896981	-1258.896037	-1258.963582
7 ^{t-Bu} open	-1071.932428	-1071.931484	-1071.999741
4 ^{t-Bu} closed	-1111.23753	-1111.236586	-1111.304907
CO ₂	-188.57746	-188.5765138	-188.6007714
4 ^{Ph} + CO ₂	-1447.462472	-1447.461527	-1447.534717
7 ^{Ph} + CO ₂	-1408.196604	-1408.19566	-1408.266961
4 ^{t-Bu} + CO ₂	-1299.808968	-1299.808024	-1299.882916
7 ^{t-Bu} + CO ₂	-1260.54783	-1260.546886	-1260.61858
H ₂	-1.16143601	-1.1604918	-1.17528635
4 ^{Ph} + H ₂	-1260.017714	-1260.01677	-1260.087252
7 ^{Ph} + H ₂	-1220.747824	-1220.746879	-1220.814944
4 ^{t-Bu} + H ₂	-1112.370605	-1112.369661	-1112.441758
7 ^{t-Bu} + H ₂	-1073.099418	-1073.098474	-1073.16693




Figure S56 Comparison of Gibbs free energies ΔG° in the gas-phase for ring closure reactions of C1, C2 and C3 linked 2-alkylphosphino-1-boraadamantanes. Energies are given in kcal mol⁻¹.




Figure S57 Comparison of Gibbs free energies in the gas-phase ΔG° and with implicit solvent model (CH₂Cl₂) $\Delta_{\text{solv}}G^\circ$ for reactions of **7^{Ph}** and **7^{t-Bu}** with BH₃-THF, CO₂ and H₂. Energies are given in kcal mol⁻¹.




Figure S58 Comparison of Gibbs free energies in the gas-phase ΔG° and with implicit solvent model (CH_2Cl_2) $\Delta_{\text{solv}}G^\circ$ for reactions of 4^{Ph} and $4^{\text{t-Bu}}$ with CO_2 and H_2 . Energies are given in kcal mol⁻¹.




Figure S59 Comparison of Gibbs free energies ΔG° in the gas-phase for adduct formation of 1-boraadamantane and different-alkylphosphines. Energies are given in kcal mol⁻¹.

Determination of the percent buried volume of 8^{t-Bu}

The values were calculated from the molecular structures of gold complex 9^{t-Bu} by using *SambVca 2.1*.^[11] Hereby, the Au-P distances was set to 2.28 Å, Bondi radii scaled by 1.17, sphere radius set to 3.5, hydrogen atoms were omitted.

Table S4. Calculated percent buried volumes % V_{bur} for selected phosphines.

Phosphine	% V_{bur}
PPh ₃	30.0 ^[12]
PCy ₃	33.2 ^[12]
P(<i>t</i> -Bu) ₃	38.0 ^[12]
8^{t-Bu}-DMAP	38.7
P(<i>o</i> -tol) ₃	39.4 ^[13]
PMes ₃	45.0 ^[13]




Figure S60 Steric map for the depiction of % V_{bur} for ligand 8^{t-Bu}.

References:

- [1] a) Y.N. Bubnov, T. V. Potapova, M. E. Gursky, *J. Organomet. Chem.* **1991**, 412, 311; b) Y. Huang, Le Zhang, W. Wei, F. Alam, T. Jiang, *Phosphorus Sulfur* **2018**, 193, 363; c) J. Meiners, A. Friedrich, E. Herdtweck, S. Schneider, *Organometallics* **2009**, 28, 6331.
- [2] M. E. Gurskii, S. Y. Erdyakov, T. V. Potapova, Y. N. Bubnov, *Russ Chem Bull* **2008**, 57, 802.
- [3] Bruker, *Apex4, SAINT, and SADABS.*, Bruker AXS Inc, Madison, Wisconsin, USA., **2021**.
- [4] G. M. Sheldrick, *Acta Crystallogr. A* **2015**, 71, 3.
- [5] G. M. Sheldrick, *Acta Crystallogr. C* **2015**, 71, 3.
- [6] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, *J. Appl. Crystallogr.* **2009**, 42, 339.
- [7] F. Neese, *WIREs Comput Mol Sci* **2022**, 12, 12753.
- [8] a) S. Grimme, J. Antony, S. Ehrlich, H. Krieg, *J. Chem. Phys.* **2010**, 132, 154104; b) S. Grimme, S. Ehrlich, L. Goerigk, *J. Comput. Chem.* **2011**, 32, 1456; c) F. Weigend, R. Ahlrichs, *Phys. Chem. Chem. Phys.* **2005**, 7, 3297.
- [9] F. Weigend, *Phys. Chem. Chem. Phys.* **2006**, 8, 1057.
- [10] V. Barone, M. Cossi, *J. Phys. Chem. A* **1998**, 102, 1995.
- [11] L. Falivene, Z. Cao, A. Petta, L. Serra, A. Poater, R. Oliva, V. Scarano, L. Cavallo, *Nat. Chem.* **2019**, 11, 872.
- [12] J. A. Werra, K. Wurst, L. B. Wilm, P. Löwe, M. B. Röthel, F. Dielmann, *Organometallics* **2023**, 42, 597.
- [13] H. Clavier, S. P. Nolan, *Chem. Commun.* **2010**, 46, 841.